Word

BLUEROCK

Status

Pending

Status Code

730

Status Date

Thursday, April 11, 2024

Serial Number

97501359

Mark Type

4000

Filing Date

Wednesday, July 13, 2022

Published for Opposition

Tuesday, September 19, 2023

Trademark Owner History

BlueRock Therapeutics LP - Owner At Publication

Classifications

5 Cells for medical or clinical use; genetic material being cells and biological tissue cultures for medical or clinical use; cell therapy and genetic medicine-based pharmaceutical and therapeutic pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; pharmaceutical and therapeutic pharmaceutical preparations in the nature of cells for human use for treating Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through cell therapy or gene therapy; cell therapy and genetic medicine-based pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through gene therapy and cell therapy

44 Medical treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; collection and preservation of human biological tissue, blood and cells for medical diagnostic testing purposes; medical diagnostic testing, monitoring and reporting services

42 Medical and scientific research services in the fields of gene therapy and cell therapy; pharmaceutical research and development services

BLUE ROCK

Trademark Events

Apr 11, 2024

Sou Extension 1 Granted

Apr 11, 2024

Sou Extension 1 Filed

Apr 11, 2024

Sou Teas Extension Received

Nov 14, 2023

Noa E-Mailed - Sou Required From Applicant

Oct 12, 2023

Teas Change Of Correspondence Received

Oct 12, 2023

Attorney/Dom.Rep.Revoked And/Or Appointed

Oct 12, 2023

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Oct 3, 2023

Withdrawal Of Attorney Granted

Oct 3, 2023

Teas Withdrawal Of Attorney Received

Sep 19, 2023

Official Gazette Publication Confirmation E-Mailed

Sep 19, 2023

Published For Opposition

Aug 30, 2023

Notification Of Notice Of Publication E-Mailed

Aug 25, 2023

Teas Change Of Correspondence Received

Aug 25, 2023

Applicant/Correspondence Changes (Non-Responsive) Entered

Aug 25, 2023

Teas Change Of Owner Address Received

Aug 15, 2023

Approved For Pub - Principal Register

Aug 15, 2023

Examiner's Amendment Entered

Aug 15, 2023

Notification Of Examiners Amendment E-Mailed

Aug 15, 2023

Examiners Amendment E-Mailed

Aug 15, 2023

Examiners Amendment -Written

Jul 31, 2023

Teas/Email Correspondence Entered

Jul 28, 2023

Correspondence Received In Law Office

Jul 28, 2023

Teas Response To Office Action Received

Apr 28, 2023

Notification Of Non-Final Action E-Mailed

Apr 28, 2023

Non-Final Action E-Mailed

Apr 28, 2023

Non-Final Action Written

Apr 27, 2023

Assigned To Examiner

Aug 2, 2022

New Application Office Supplied Data Entered

Jul 16, 2022

New Application Entered